Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stake Raised by Fox Run Management L.L.C.

Fox Run Management L.L.C. boosted its holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 54.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,073 shares of the company’s stock after acquiring an additional 7,040 shares during the quarter. Fox Run Management L.L.C.’s holdings in Treace Medical Concepts were worth $149,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of Treace Medical Concepts by 215.1% during the third quarter. JPMorgan Chase & Co. now owns 1,262,235 shares of the company’s stock valued at $7,321,000 after purchasing an additional 861,689 shares during the period. William Blair Investment Management LLC increased its stake in Treace Medical Concepts by 22.9% during the 4th quarter. William Blair Investment Management LLC now owns 2,938,848 shares of the company’s stock valued at $21,865,000 after buying an additional 546,787 shares during the period. Barclays PLC raised its position in shares of Treace Medical Concepts by 352.2% during the 3rd quarter. Barclays PLC now owns 79,696 shares of the company’s stock worth $460,000 after buying an additional 62,073 shares in the last quarter. FMR LLC lifted its stake in shares of Treace Medical Concepts by 228.5% in the 3rd quarter. FMR LLC now owns 78,135 shares of the company’s stock worth $453,000 after acquiring an additional 54,353 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Treace Medical Concepts during the fourth quarter valued at approximately $392,000. Institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Stock Performance

Shares of NASDAQ TMCI opened at $8.45 on Friday. Treace Medical Concepts, Inc. has a 52-week low of $3.92 and a 52-week high of $13.24. The stock has a market capitalization of $529.13 million, a price-to-earnings ratio of -8.54 and a beta of 0.77. The company has a quick ratio of 2.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $9.24 and its 200 day simple moving average is $7.56.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TMCI shares. JPMorgan Chase & Co. restated a “neutral” rating and issued a $8.00 target price on shares of Treace Medical Concepts in a research report on Tuesday, December 17th. Truist Financial cut their price objective on Treace Medical Concepts from $10.00 to $9.50 and set a “hold” rating for the company in a report on Thursday, March 13th. BTIG Research raised Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Tuesday, February 4th. Finally, Lake Street Capital began coverage on shares of Treace Medical Concepts in a report on Tuesday, December 31st. They issued a “buy” rating and a $14.50 price target for the company. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Treace Medical Concepts presently has a consensus rating of “Hold” and an average price target of $10.14.

Insider Activity at Treace Medical Concepts

In other Treace Medical Concepts news, insider Sean F. Scanlan sold 50,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $7.97, for a total value of $398,500.00. Following the completion of the transaction, the insider now directly owns 364,081 shares in the company, valued at $2,901,725.57. This trade represents a 12.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 24.43% of the stock is currently owned by corporate insiders.

Treace Medical Concepts Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.